$0.4552
0.0071.56%
Last update: Nov 10, 8:47 AM
Humacyte Inc
HUMANASDAQ
Humacyte fell 66.3% from $1.35 to $0.46, behind the S&P 500's +10.5%. Its worst day was Mar 19 (−19.4%), and its low came Oct 14 at $0.35.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.11 beat the $-0.16 estimate on $753,000.00 revenue (est. $921,698.00).
−2.3% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Humacyte shares rose 30.0%, while the S&P 500 rose 0.5%.
+30.0%, the year's best day · S&P 500 +0.5%
Humacyte shares fell 19.4%, while the S&P 500 fell 0.5%.
−19.4%, the year's worst day, on 52M shares, the year's heaviest volume · S&P 500 −0.5%
EPS of $-0.13 beat the $-0.13 estimate on $467,000.00 revenue (est. $1.4M).
−13.2% · S&P 500 −1.7%
EPS of $-0.09 beat the $-0.11 estimate on $495,000.00 revenue (est. $1.4M).
+24.2% · S&P 500 +0.6%
Humacyte closed at its highest level of the year, 10.4% above where the year started.
+6.4% · S&P 500 +0.4%
EPS of $-0.16 missed the $-0.10 estimate on $406,000.00 revenue (est. $1.2M).
−6.3% · S&P 500 +0.3%
Humacyte closed at its lowest level of the year, 73.8% below where the year started.
−1.3% · S&P 500 −1.1%
Where it ended: a close of $0.46 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.08, revenue est. $788,000.00).
Nothing in the past 12 months.
All HUMA dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for HUMA and SPY from Benzinga historical bars. Not investment advice.
